MSB 0.61% $4.91 mesoblast limited

Analysis of the EAP, page-14

  1. 6,064 Posts.
    lightbulb Created with Sketch. 1005
    Welcome @LeftYahoo

    I’ll keep it simple for those that are confused

    Most COVID-19 deaths occur due to a cytokine storm — a process whereby the body’s own immune response runs wild causing acute and often fatal inflammation.

    Vaccines are attempting to stop the storm from occurring. That’s easier said than done especially when mutations are involved.

    Mesoblast role is to treat moderate/sever cases in ICU who have cytokine storm episodes developed ARDS and progressed to ventilators and have failed other treatments.

    Two injections of remestemcel-L five days apart to dampen the immune system with the aim to ;

    1. Keep the patient alive (survival)
    2. Get the patient off ventilators
    3. Reduce Hospitalization time and get the patient home with quality of life.

    Early results indicate huge promise for increasing survival, ventilator dependence and reduced hospitalization.

    Bottom line cytokine storms and aggressive inflammation aren’t just caused by COVID and this is where Mesoblast has a niche with ARDS.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $2.880B
Open High Low Value Volume
$4.96 $5.00 $4.90 $27.35M 5.546M

Buyers (Bids)

No. Vol. Price($)
35 132759 $4.90

Sellers (Offers)

Price($) Vol. No.
$4.92 26502 3
View Market Depth
Last trade - 16.10pm 25/09/2020 (20 minute delay) ?
-0.030 ( 0.87 %)
Open High Low Volume
$4.96 $5.00 $4.89 1281491
Last updated 15.59pm 25/09/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.